Mary Ann Liebert, Inc., publishers

A new study describes how NS1, a protein produced by influenza A viruses, suppresses the body's immune responses to viral infection.

Mary Ann Liebert, Inc., publishers is pleased to announce Sergi Ferré, MD, PhD, has been appointed Editor-in-Chief of Journal of Caffeine Research. Dr.

A new study of patients who underwent curative surgical removal of a pancreatic ductal adenocarcinoma showed that two of the nine preoperative factors analyzed were strongly predictive of poor prognosis regardless of the tumor stage.

A study comparing the safety and efficacy of SAR342434, a biosimilar (follow-on form) of insulin lispro-Humalog®, found it to be comparable to that of the brand name drug in patients also using insulin glargine.

Researchers have demonstrated the ability to generate dopaminergic neurons in the laboratory from induced pluripotent stem cells (iPSCs) derived from fibroblast cells of adult marmoset monkeys.

In a forthcoming special issue of Tissue Engineeringon "Strategic Directions in Musculoskeletal Tissue Engineering," Guest Editors Megan Killian, PhD, University of Delaware, MD and Anne Gingery, PhD, Mayo Clinic, MI have compiled a diverse group of...

In the destructive cycle that leads to and perpetuates type 2 diabetes, driven by overeating, excessive blood glucose, defective pancreatic beta cell function, and imbalances in insulin-regulating hormone levels, the gut appears to play a key role.

Researchers compared the effects of three bone growth factors to bone morphogenetic protein 2 (BMP2)--the most commonly used agent for repair of large bone defects, which is not without risks at the doses required--and showed significant bone-healing...

Unlike the one-size-fits-all, homogeneous approach to tissue engineering for cartilage replacement, a new study reports the ability to encapsulate cartilage-forming chondrocytes and mesenchymal stem cells in 3D hydrogels within a stiffness gradient.

A new study assessed the safety, tolerability, and effectiveness of extended-release guanfacine in children 6-17 years of age who have chronic tic disorders including Tourette's disorder.